Search results for "COMPOUND"

showing 10 items of 35174 documents

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative…

2010

Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major patients by means of quantitative magnetic resonance imaging. Design and Methods From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalasse…

medicine.medical_specialtyLiver Iron ConcentrationthalassemiaThalassemiairon chelation therapycardiac magnetic resonance imagingGastroenterologythalassemia; iron chelation therapy; cardiac magnetic resonance imagingNOchemistry.chemical_compoundCardiac magnetic resonance imagingInternal medicinemedicinemedicine.diagnostic_testbusiness.industryDeferasiroxBeta thalassemiaMagnetic resonance imagingHematologymedicine.diseaseSurgeryDeferoxaminechemistrybusinessDeferipronemedicine.drug
researchProduct

Positive Airway Pressure Treatment Reduces Glycated Hemoglobin (HbA1c) Levels in Obstructive Sleep Apnea Patients: Longitudinal Data from the Esada

2019

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN

medicine.medical_specialtyLongitudinal dataGastroenterologyComorbidities03 medical and health sciencesHba1c levelchemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinePositive airway pressuremedicine030212 general & internal medicinebusiness.industryType 2 Diabetes MellitusSleep apneaSystemic effectmedicine.diseaserespiratory tract diseasesObstructive sleep apnea030228 respiratory systemApnea–hypopnea indexchemistryCardiologyGlycated hemoglobinbusinessBody mass indexTurkish Thoracic Journal
researchProduct

El papel de la dislipemia aterogénica en las guías de práctica clínica.

2016

Background and objective Atherogenic dyslipidaemia is underdiagnosed, undertreated, and under-controlled. The aim of the present study was to assess the positioning of clinical guidelines as regards atherogenic dyslipidaemia. Material and method The major clinical guidelines of scientific societies or official agencies issued between January 1, 2012 and March 31, 2015 were collected from the MEDLINE database. High-density lipoprotein (HDL) cholesterol, triglycerides, atherogenic dyslipidaemia, non-HDL cholesterol, and apolipoprotein (apo) B were gathered from the 10 selected guidelines, and it was assessed whether these parameters were considered a cardiovascular risk factor, a therapeutic …

medicine.medical_specialtyLow HDL-cholesterolendocrine system diseasesApolipoprotein BNice030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCardiovascular preventionInternal medicinemental disordersmedicinePharmacology (medical)cardiovascular diseases030212 general & internal medicineRisk factorcomputer.programming_languagebiologybusiness.industryCholesterolnutritional and metabolic diseasesClinical Practicechemistrybiology.proteinlipids (amino acids peptides and proteins)Atherogenic dyslipidaemia Cardiovascular prevention Cholesterol Colesterol Dislipemia aterogénica Guías de práctica clínica Lipids Lípidos Practice guidelines Prevención cardiovascular Triglicéridos TriglyceridesCardiology and Cardiovascular MedicinebusinesscomputerLipoprotein
researchProduct

Low-density lipoprotein size and cardiovascular risk assessment

2017

A predominance of small, dense low-density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease and evidences suggests that both quality (particularly small, dense LDL) and quantity may increase cardiovascular risk. However, other authors have suggested that LDL size measurement does not add information beyond that obtained by measuring LDL concentration, triglyceride levels and HDL concentrations. Therefore, it remains debatable whether to measure LDL particle size in cardiovascular …

medicine.medical_specialtyLow-density lipoprotein cardiovascular risk610 Medicine & health2700 General MedicineRisk Assessment142-005 142-005chemistry.chemical_compoundClofibric AcidRisk FactorsInternal medicinemedicineHumansClinical significanceRisk factorParticle SizeNational Cholesterol Education ProgramHypolipidemic AgentsTriglyceridebusiness.industryVascular diseaseAnticholesteremic AgentsConfoundingGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinologychemistryCardiovascular DiseasesLow-density lipoproteinCardiologylipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessment
researchProduct

Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.

2007

Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40…

medicine.medical_specialtyLung Neoplasmsmedicine.drug_classAdministration OralPharmacologyVinorelbineVinblastineRoute of administrationchemistry.chemical_compoundOral administrationCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsMedicineAntiemeticHumansPharmacology (medical)Randomized Controlled Trials as Topicbusiness.industryCombination chemotherapyVinorelbineAntineoplastic Agents PhytogenicCombined Modality TherapyGemcitabineCarboplatinBioavailabilitySurgerychemistryOral vinorelbine small cell lung cancer.businessmedicine.drugDrugs
researchProduct

Do nutritional supplements have a role in age macular degeneration prevention?

2013

Purpose. To review the proposed pathogenic mechanisms of age macular degeneration (AMD), as well as the role of antioxidants (AOX) and omega-3 fatty acids (ω-3) supplements in AMD prevention.Materials and Methods. Current knowledge on the cellular/molecular mechanisms of AMD and the epidemiologic/experimental studies on the effects of AOX andω-3 were addressed all together with the scientific evidence and the personal opinion of professionals involved in the Retina Group of the OFTARED (Spain).Results. High dietary intakes ofω-3 and macular pigments lutein/zeaxanthin are associated with lower risk of prevalence and incidence in AMD. The Age-Related Eye Disease study (AREDS) showed a benefic…

medicine.medical_specialtyLuteineicosapentaenoic acidgenetic structuresmedicine.medical_treatmentSuplements nutritiusPhysiologypigment epithelial-celllsReview ArticleLower riskAntioxidantsclinical-trialchemistry.chemical_compoundlcsh:Ophthalmologybeta-CaroteneOPHTHALMOLOGYOmega-3 fatty acidsMedicineoxidative stressbusiness.industryVitamin Evitamin-EPreventionblue mountains eyeMacular degenerationMicronutrientmedicine.diseaseDietary supplementsEicosapentaenoic acidbeaver dam eyeAge macular degeneration (AMD)Retinal diseaseseye diseasesSurgeryZeaxanthinOphthalmologybeta-caroteneMalalties de la retinachemistrylcsh:RE1-994fatty-acid compositionsense organsbusinessgrowth-factor VEGFJournal of ophthalmology
researchProduct

Effects of 1-(halogenalkoxy)alkyl-5-fluorouracil derivatives on cell growth, cell volume and nucleus size of mouse lymphoma cells.

1992

The effects of three 1-(halogenalkoxy)alkyl-5-fluorouracil derivatives on cultured mouse lymphoma cells were studied and compared with those of N-methyl-bis-(2-chloroethyl)amine hydrochloride (Lost). The derivatives exert only little influence on cell proliferation and cell volume. However, all derivatives cause a concentration-dependent nucleus contraction, probably due to DNA cross-linkings. Bromodesoxyuridine modulates the effects of the derivatives on the DNA, leading to swelling of the nucleus, which may be caused by DNA strand-breaks. It is suggested that the derivatives exert synergistic effects with other factors. It is concluded that these studies are suitable for the prescreening …

medicine.medical_specialtyLymphomaHydrochlorideDNA damageBiologychemistry.chemical_compoundMiceInternal medicineDrug DiscoverymedicineTumor Cells CulturedAnimalsPharmacology (medical)PharmacologyCell NucleusCell growthBiological activityGeneral Medicinemedicine.diseaseMolecular biologyIn vitroLymphomaInfectious Diseasesmedicine.anatomical_structureEndocrinologyOncologychemistryFluorouracilNucleusDNACell DivisionChemotherapy
researchProduct

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting

2019

Real-life data confirming the favourable renal outcome in patients with heart failure (HF) treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We evaluated the renal effects of Sacubitril/Valsartan in a real-life sample of HF patients. Observational analysis of 54 consecutive outpatients affected by HF with reduced ejection fraction (HFrEF) and clinical indication for Sacubitril/Valsartan. Patients were evaluated at baseline (T0) and after six (T6) and twelve (T12) months after initiating Sacubitril/Valsartan and compared with a group of 30 historical controls. Mean age: 65.5 ± 11.7 years. Older patients: 29 (53.7%). Mean baseline estimated glomeru…

medicine.medical_specialtyMEDLINETetrazolesHeart failureLifeInternal MedicinemedicineHumansKidney dysfunctionSacubitril-ValsartanIntensive care medicinebusiness.industryAminobutyratesBiphenyl CompoundsFollow up studiesSacubitril/Valsartanmedicine.diseaseIm - OriginalDrug CombinationsValsartanHeart failureBlood pressureEmergency MedicineValsartanbusinessSacubitril ValsartanFollow-Up StudiesRenal functionmedicine.drug
researchProduct

Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA(1-64)) in the rat heart

2010

Cytoskeleton scaffold in cardiac myocytes provides structural support and compartmentalization of intracellular components. It is implicated in cardiac pathologies including hypertrophy and failure, playing a key role in the determinism of contractile and diastolic dysfunctions. Chromogranin A (CgA) and its derived peptides have revealed themselves as novel cardiovascular modulators. In humans, normal CgA levels considerably increase in several pathologies, including heart failure. Recent data have shown on the unstimulated rat heart that human recombinant Vasostatin-1 (hrVS-1) and rat chromogranin A 1-64 (rCgA(1-64)) induce negative inotropic and lusitropic effects counteracting the beta-a…

medicine.medical_specialtyMESH: RatsPhysiologyPhalloidin[SDV]Life Sciences [q-bio]Clinical BiochemistryMESH: Myocytes Cardiacmacromolecular substancesBiologyBiochemistryWortmanninCellular and Molecular Neurosciencechemistry.chemical_compoundEndocrinologyInternal medicineMyosinmedicineMESH: CytoskeletonMyocyteMESH: AnimalsCytoskeletonActinMESH: In Vitro TechniquesMESH: HumansSettore BIO/16 - Anatomia UmanaChromogranin AMESH: Rats WistarMESH: MaleCell biologyMESH: Cell LineMESH: Heart[SDV] Life Sciences [q-bio]EndocrinologychemistryInotropismVasostatin Rat CgA1-64 Rat Langendorff heart Inotropy Lusitropy Cardiomyocytes Cytoskeletonbiology.proteinMESH: Chromogranin A
researchProduct

Is there a critical tissue oxygen tension for bioenergetic status and cellular pH regulation in solid tumors?

1996

Bioenergetic and metabolic status have been correlated with tissue oxygenation in murine fibrosarcomas (FSaII) of varying sizes (44-600 mm3). Ratios of beta-nucleoside triphosphates to inorganic phosphate (beta NTP/P) and phosphocreatine to inorganic phosphate (PCr/P(i)) ratios derived from 31P nuclear magnetic resonance spectroscopy (NMR) were positively correlated to median tissue O2 tension (pO2) values using O2-sensitive needle electrodes. pH declined during growth with intracellular acidosis being evident in tumors350 mm3. Whereas lactic acid formation greatly contributed to this decline in small and medium-sized tumors, adenosine triphosphate (ATP) hydrolysis and slowing down of the a…

medicine.medical_specialtyMagnetic Resonance SpectroscopyAlkalosisBioenergeticsFibrosarcomaPartial PressureAdenylate kinasePhosphocreatineMiceCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicinemedicineAnimalsHomeostasisEnergy chargeMolecular BiologyPharmacologyAdenine NucleotidesCell BiologyHydrogen-Ion Concentrationmedicine.diseaseLactic acidOxygenEndocrinologychemistryMolecular MedicineEnergy MetabolismAdenosine triphosphateIntracellularExperientia
researchProduct